Inside Kenya's Ozempic Moment: Weight Loss Drugs Arrive as Obesity Burden Mounts

Kenya's obesity and diabetes burden has been growing quietly for two decades — not at the dramatic rates seen in the Gulf states or North America, but at a pace that health economists say will generate a public health crisis within a generation if diet and physical activity patterns in urban Kenya do not change.

Into this context, Novo Nordisk's Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for obesity) have arrived in Nairobi pharmacies through two licensed importers, available for the first time without the need for a medical trip to Dubai or South Africa. The drugs, which mimic the gut hormone GLP-1 to suppress appetite and regulate blood sugar, have transformed diabetes and obesity management globally and generated the most intense prescription demand in pharmaceutical history.

A monthly supply of Wegovy at the doses required for meaningful weight loss costs between Ksh28,000 and Ksh35,000 at Nairobi pharmacies — approximately double the minimum monthly wage and far above what any public health insurance scheme currently covers. Ozempic, prescribed for diabetes, is marginally cheaper but still beyond the means of the majority of Kenya's 3.6 million registered diabetes patients.

Endocrinologist Dr Mwaura Kamau at Kenyatta National Hospital welcomed the arrival but expressed frustration at the access gap. "These are transformative drugs. My patients who have tried them are reporting results we could not achieve with other medications. But I can only prescribe them to patients who can pay. That is a moral problem that is not mine to solve alone — it requires policy."

SHA and the previous NHIF scheme do not currently cover GLP-1 medications, and the Ministry of Health has not commented on whether inclusion in the national formulary is being considered. In the United States, the budget debate over Medicaid coverage of Wegovy suggests that even wealthy health systems are struggling with the cost implications. Kenya's choices will determine whether these drugs reach public health impact or remain luxury medicine for the few.